

# Pathophysiology of Dupuytren's Contracture

<b>Submission date</b> 11/08/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 11/08/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 18/04/2017	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Liaquat Suleman-Verjee

**Contact details**  
Imperial College London  
Kennedy Institute of Rheumatology Division  
65 Aspenlea Road  
London  
United Kingdom  
W6 8LH

## Additional identifiers

**Protocol serial number**  
6585

## Study information

**Scientific Title**  
Pathophysiology of Dupuytren's Contracture

### Study objectives

Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following

excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

MREC approved, ref: 06/Q0403/95

**Study design**

Multicentre non-randomised interventional treatment trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery

**Interventions**

Elucidate the exact role of tenascin-C in Dupuytren's disease

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/07/2011

**Eligibility****Key inclusion criteria**

Not provided at time of registration

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

02/11/2006

**Date of final enrolment**

31/07/2011

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Imperial College London

London

United Kingdom

W6 8LH

**Sponsor information****Organisation**

Royal College of Surgeons of England (UK)

**ROR**

<https://ror.org/02qrg5a24>

**Funder(s)**

**Funder type**

Charity

**Funder Name**

Healing Foundation

**Alternative Name(s)****Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration